Breast Cancer Foundation NZ
TRAIL
Early Breast Cancer clinical trials for ER+
The purpose of this study is to determine if breast cancer genetic material (known as circulating tumour DNA (ctDNA) can be detected in the bloodstream. It is hoped that this research will demonstrate the utility of this circulating material as an early marker of residual or recurrent breast cancer activity after treatment
Who is it for?
You may be eligible for this study if you are aged 18 or over and have confirmed non-metastatic adenocarcinoma of the breast.
Study details
You will require a blood test every three months for two years from the time of registration to the main study. As part of this study, you will also need to complete questionnaires that ask about your feelings towards the regular blood tests and thoughts of cancer return. If the ctDNA levels are detected in your bloodstream during the two year period, you will be asked to return to have a CT and/or bone scan.
Australia
Peter MacCallum Cancer Centre, Melbourne
Contact:
Peter MacCallum Cancer Centre: Professor Sarah-Jane DawsonIf you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Early Breast Cancer
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.